

Joe Lombardo, *Governor*
James Humm, *Executive Director*



Adriana Guzmán Fralick, *Chair*
Riana Durrett, *Vice Chair*
Hon. Michael Douglas, *Member*
Jerrie Merritt, *Member*
Dr. Vicki Mazzorana, *Member*

REGULATORY WORKSHOP
NOTICE AND AGENDA

April 30, 2024
10:00 am

Cannabis Compliance Board
700 E. Warm Springs Road, Room 150
Las Vegas, Nevada 89119

The Agency will hold a workshop to solicit comments from interested parties regarding proposed changes to the permanent regulations of the Cannabis Compliance Board, LCB File No. TBD, which revises provisions governing proceedings before the Board, matters related to the Cannabis Independent Testing Laboratory inspections, certifications, and policies and procedures.

A copy of the regulations referenced below can be found on the Agency's website at <https://ccb.nv.gov/public-meetings/#public-meetings-2> and at the Nevada Legislature's website at <https://www.leg.state.nv.us/App/Notice/A/>

The public may attend the workshop in person in Las Vegas. The public may also view the meeting at the time noticed herein by live stream link located at: <https://ccb.nv.gov/public-meetings/#public-meetings-2> and may submit public comment as set forth below in the Public Notice section.

I. Public Comment

II. Proposed Amendments and Additions to Nevada Cannabis Compliance Regulations

Cannabis Independent Testing Laboratory

A. **Regulation 5.** (for discussion only)

1. NCCR 5.075 Authority of Board and Executive Director relating to inspections and investigations, summoning of witnesses and issuance of subpoenas, administration of oaths and administration of provisions of chapter.

B. **Regulation 7.** (for discussion only)

1. NCCR 7.035 Storage and location of products; disclosure of cannabis testing facility performing quality assurance tests upon request of consumer; approved sources of products for sale; maintenance and availability of certificate of analysis; exemption for industrial hemp.

C. **Regulation 11.** (for discussion only)

1. NCCR 11.010 Employment, qualifications and duties of scientific director; inspection of testing laboratory upon appointment of new director.
2. NCCR 11.015 Requirements for testing laboratory to handle, test or analyze cannabis.
3. NCCR 11.020 Agreement to become accredited within 1 year after licensure; provision of annual inspection report to Board; inspection by accrediting organization is not substitute for inspection by Board.
4. NCCR 11.025 Adherence to general laboratory standards, practices, procedures and programs; inspection by Board or authorized third party; adoption of publications by reference.
5. NCCR 11.030 Establishment of policies for adequate chain of custody and requirements for samples of products provided to testing laboratory.
6. NCCR 11.045 Limited testing for research and development purposes.
7. NCCR 11.050 Required quality assurance tests; submission of wet cannabis for testing.
8. NCCR 11.053 Requirements for instrument calibration and quality control. (new)

9. NCCR 11.060 Performance of testing to verify homogeneity of potency of edible cannabis products.
10. NCCR 11.065 Use of approved pesticides by cannabis establishment; performance of pesticide residue analysis by testing laboratory.
11. NCCR 11.070 Testing: Selection of representative samples and random samples; segregation period for entire lot; duties of testing laboratory; disposal of lot if sample fails test; release of lot if sample passes test; filing of electronic copy of certificate of analysis for tests performed by testing laboratory; grounds for disciplinary action for failure to comply.
12. NCCR 11.075 Testing: Authorized use of cannabis upon failure of microbial screening; automatic failure to pass; request for retest; retest for pesticide residue must be performed by State Department of Agriculture; effect of passing or failing retest.
13. NCCR 11.085 Random quality assurance compliance checks; costs for screening or testing.

III. Public Comment

IV. Adjournment

Public Notice

The public is hereby noticed that items on this agenda are stacked. Items may be taken out of order, two or more agenda items may be combined for consideration, and/or at any time an agenda item may be removed from the agenda or discussion delayed.

The Cannabis Compliance Board (CCB) will take public comment on any matters within its jurisdiction, control, or advisory power. The Board is not permitted to deliberate or take action on any items raised during the public comment period until the matter itself has been specifically included on an agenda as an item upon which action may be taken by the Board. Comments by the public may be limited to three minutes as a reasonable time, place, and manner restriction, but may not be limited upon viewpoint. If a member of the public is unable to attend the meeting in person and would like to provide public comment during the meeting through remote appearance, they can submit a request via email before the scheduled meeting to regulations@ccb.nv.gov to receive instructions to join the meeting remotely. The CCB is not responsible for technical difficulties a member of the public may experience in connecting to the meeting remotely. Comments by the public may be emailed to regulations@ccb.nv.gov by 5:00 p.m. the day before the scheduled meeting and include the commenter's full name. Content may be redacted due to inappropriate language. All written public comments shall, in their entirety, be included as part of the public record. Prior to the commencement and conclusion of a contested case or a quasi-judicial proceeding that may affect the due process rights of an individual, the Board may refuse to consider public comment regarding the matter pursuant to NRS 678A.560 and NCCR 4.080. In the event technical difficulties prevent these proceedings from being broadcast, the CCB, at its discretion, may conduct the meeting without the proceedings being broadcast.

We are pleased to make reasonable accommodations for members of the public who are disabled and wish to attend the meeting. If special arrangements for the meeting are necessary, please notify the Cannabis Compliance Board via email at regulations@ccb.nv.gov, in writing at Cannabis Compliance Board, 700 E. Warm Springs Rd., Suite 100, Las Vegas, Nevada 89119 or by calling 702-486-8241 as soon as possible.

This agenda has been emailed for posting at the following locations: Cannabis Compliance Board 700 E. Warm Springs Rd., Suite 100, Las Vegas, Nevada; Cannabis Compliance Board 3850 Arrowhead Dr., Carson City, Nevada; The Legislative Building – Capitol Complex, Carson City; The Nevada State Library 100 Stewart Street, Carson City; on the official website of the State of Nevada at <https://notice.nv.gov>, pursuant to NRS 232.2175; on the Legislative website at <https://www.leg.state.nv.us/>, on the Cannabis Compliance Board's website at <https://ccb.nv.gov> and to the Interested Parties mailing list maintained by the agency.

In the event there are supporting materials available for items on this agenda, such materials will be produced upon request pursuant to NRS 241.020(7) and (8) by submitting a request via email to regulations@ccb.nv.gov or via mail at 700 E. Warm Springs Rd., Suite 100, Las Vegas, Nevada, 89119. Supporting materials may also be available at the Cannabis Compliance Board's website at <https://ccb.nv.gov/public-meetings/>

**Proposed Changes to NCCR Regulation 5
LICENSING, BACKGROUND CHECKS, AND REGISTRATION CARDS**

New

~~Deleted~~

5.075 Authority of Board and Executive Director relating to inspections and investigations, summoning of witnesses and issuance of subpoenas, administration of oaths and administration of provisions of chapter.

1. Submission of an application for a license for a cannabis establishment constitutes permission for entry to and reasonable inspection of the cannabis establishment by the Board and Board Agents, with or without notice. An inspector conducting an inspection pursuant to this section does not need to be accompanied during the inspection.
2. The Executive Director may, upon receipt of a complaint against a cannabis establishment, except for a complaint concerning the cost of services, a complaint concerning the efficacy of cannabis or a complaint related to consumer service issues, conduct an investigation during the operating hours of the cannabis establishment, with or without notice, into the premises, facilities, qualifications of personnel, methods of operation, policies, procedures and records of that cannabis establishment or any other cannabis establishment which may have information pertinent to the complaint.
3. Board Agents may enter and inspect any building or premises at any time, with or without notice, to:
 - (a) Secure compliance with any provision of the NCCR or Title 56 of NRS;
 - (b) Prevent a violation of any provision of the NCCR or Title 56 of NRS; or
 - (c) Conduct an unannounced inspection of a cannabis establishment in response to an allegation of noncompliance with the NCCR or Title 56 of NRS.
4. The Board may:
 - (a) Summon witnesses to appear and testify on any subject material to its responsibilities under this chapter or Title 56 of NRS. No property owner and no officer, director, superintendent, manager or agent of any company or corporation, whose property is wholly in one county, shall be required to appear, without his or her consent, at a place other than the county seat or at the nearest town to his or her place of residence or the principal place of business of such company or corporation. Such summons may be served by personal service by the Executive Director or his or her agent or by the sheriff of the county.
 - (b) Except as otherwise provided in this paragraph, issue subpoenas to compel the attendance of witnesses and the production of books and papers and may seek to enforce the subpoenas by petition to any court of competent jurisdiction in the manner provided by law. The Board will not issue a subpoena to compel the production of books and papers that contain individually identifiable health information.
5. Any member of the Board, the Executive Director or any officer of the Board designated by the Board or Executive Director may administer oaths to witnesses.

6. The Board and Board Agents may:
 - (a) Inspect and examine all premises wherein cannabis is manufactured, sold or distributed;
 - (b) Inspect all equipment and supplies in, upon or about such premises;
 - (c) Summarily seize and remove from such premises any cannabis or cannabis products and impound any equipment, supplies, documents or records for the purpose of examination and inspection;
 - (d) Demand access to and inspect, examine, photocopy and audit all papers, books and records of any applicant or licensee, on his or her premises, or elsewhere as practicable, and in the presence of the applicant or licensee, or his or her agent, relating to the gross income produced by any cannabis establishment, and require verification of income, and all other matters affecting the enforcement of the policy or any of the provisions of this chapter or any chapter of Title 56 of NRS; and
 - (e) Demand access to and inspect, examine, photocopy and audit all papers, books and records of any affiliate of a licensee whom the Board knows or reasonably suspects is involved in the financing, operation or management of the licensee. The inspection, examination, photocopying and audit may take place on the premises of the affiliate or another location, as practicable, and in the presence of the affiliate or its agent.
7. Board Agents will enter and inspect ~~at least annually~~, with or without notice, each building or the premises of a cannabis establishment to ensure compliance with the provisions of this chapter and Title 56 of NRS. All cannabis establishments may be inspected at least annually except that cannabis independent testing laboratories may be inspected at least biennially, with interim follow-up activities at least annually. Nothing in this subsection shall be construed to prohibit an appropriate local administrative authority from conducting an inspection of the facilities or operations of a cannabis establishment as provided by the ordinance of a local government.
8. Board Agents will enter and inspect, with or without notice, any building or premises operated by a cannabis establishment within 72 hours after the Board is notified that the cannabis establishment is operating without a license for the cannabis establishment.
9. Board Agents will inspect the medical cannabis establishment and the cannabis establishment of a dual licensee at the same time using the same inspection team to ensure consistency and efficiency. Board Agents will conduct such an inspection in a manner which is not unduly burdensome for the dual licensee.
10. The Board or Board Agents may consult with any person or entity, as needed, in any of the Board's audits, inspections, and/or investigations. This includes, but is not limited to, allowing such persons or staff from said entities to accompany Board Agents during inspections, and/or investigations.
11. The Board will administer the provisions of the NCCR and Title 56 of NRS for the protection of the public and in the public interest in accordance with the policy of this State.
12. As used in this section, "individually identifiable health information" means information which identifies a natural person, or from which the identity of a natural person may reasonably be ascertained, and which relates to:
 - (a) The past, present or future physical or mental health or condition of the person or
 - (b) The provision of health care to the person.

Proposed Changes to NCCR Regulation 7
CANNABIS SALES FACILITY

New

~~Deleted~~

7.035 Storage and location of products; disclosure of cannabis testing facility performing quality assurance tests upon request of consumer; approved sources of products for sale; maintenance and availability of certificate of analysis; exemption for industrial hemp.

1. A cannabis sales facility must store all usable cannabis, concentrated cannabis and cannabis products behind a counter or other barrier to ensure a consumer does not have direct access to the cannabis, concentrated cannabis or cannabis products.
2. Upon the request of a consumer, a cannabis sales facility must disclose the name of the cannabis testing facility which performed the required quality assurance tests for the cannabis sales facility and provide a copy of the corresponding certificate of analysis and soil amendment to the consumer.
3. A cannabis sales facility may only sell usable cannabis obtained from a cannabis cultivation facility in this State.
4. Except as otherwise provided in subsection 6, a cannabis sales facility may only sell concentrated cannabis and cannabis products obtained from a cannabis product manufacturing facility in this State.
5. ~~Except as otherwise provided in subsection 6, a~~ A cannabis sales facility may not sell a product other than usable cannabis, concentrated cannabis or cannabis products which contain any level of THC or CBD without the approval of the appropriate Board Agent. Each cannabis sales facility shall maintain a file which contains a certificate of analysis for any such approved product at the cannabis sales facility and shall make the file available for review upon request.
6. The provisions of subsection 4 does not apply to industrial hemp, as defined in NRS 557.040, which is certified and registered with the State Department of Agriculture.

Proposed Changes to NCCR Regulation 11
CANNABIS INDEPENDENT TESTING LABORATORY

New

~~Deleted~~

11.010 Employment, qualifications and duties of scientific director; inspection of testing laboratory upon appointment of new director.

1. Each cannabis independent testing laboratory must employ a scientific director who must reside within 200 miles of the laboratory, and shall be responsible for:
 - (a) Establishing and maintaining a quality control and quality assurance program that ensures the quality of the cannabis independent testing laboratory's services, and that is capable of identifying any failure of quality when it occurs;
 - (b) Ensuring safety and hazardous substance control in the laboratory;
 - ~~(b)~~ (c) Supervising all staff of the cannabis independent testing laboratory; and
 - (d) Reviewing all new technical policies and procedures, as well as substantial changes to existing technical policies and procedures, prior to implementation. These reviews must be documented and may not be delegated;
 - (e) Ensuring technical policies and procedures are reviewed at least biennially thereafter, with documentation of this review. This review may be delegated to a knowledgeable person, and must ensure technical policies and procedures are complete, current, and scientifically valid and relevant; and
 - ~~(e)~~ (f) Actively participating in the operation of the cannabis independent testing laboratory to the extent necessary to assure compliance with the NCCRs and Title 56 of NRS.
2. The scientific director of a cannabis independent testing laboratory must have earned:
 - (a) A doctorate degree in science from an accredited college or university and have at least 2 years of post-degree laboratory experience;
 - (b) A master's degree in science from an accredited college or university and have at least 4 years of post-degree laboratory experience; or
 - (c) A bachelor's degree in science from an accredited college or university and have at least 6 years of post-degree laboratory experience.
3. If a scientific director is no longer employed by a cannabis independent testing laboratory, the cannabis independent testing laboratory shall not be permitted to conduct any testing. An interim director that meets the minimum qualifications may be appointed for no more than ~~90~~ 60 days unless an extension is granted by the appropriate Board Agent.
4. A cannabis independent testing laboratory shall ~~immediately~~ inform the Board within 72 hours upon the appointment of a new scientific director or interim director.
5. A scientific director shall be available to the personnel of a testing laboratory, in person or by telephonic or other electronic means, for any necessary consultation.
6. The scientific director must be on the premises of the testing laboratory at least ~~5~~ 10 workdays each month. If circumstances temporarily prevent the scientific director from meeting this requirement, the laboratory shall appoint an interim director who meets the minimum qualifications for the necessary length of time, not to exceed 60 days, unless an extension is granted by the appropriate Board Agent.

(Amended: 8/2021)

11.015 Requirements for testing laboratory to handle, test or analyze cannabis.

1. A cannabis independent testing laboratory shall not handle, test or analyze cannabis unless:
 - (a) The cannabis independent testing laboratory has been issued a license;
 - (b) The cannabis independent testing laboratory is independent from all other persons involved in the cannabis industry in Nevada; and
 - (c) No person with a direct or indirect interest in the cannabis independent testing laboratory has a direct or indirect financial interest in:
 - (1) A cannabis sales facility;
 - (2) A cannabis production facility;
 - (3) A cannabis cultivation facility;
 - (4) A cannabis distributor;
 - (5) A provider of health care who provides or has provided written documentation for the issuance of registry identification cards or letters of approval;
 - (6) Any other entity that may benefit from the cultivation, manufacture, dispensing, sale, purchase or use of cannabis or cannabis products, or
 - (7) A cannabis consumption lounge.
2. A cannabis independent testing laboratory shall implement business practices which are structured and managed so as to safeguard impartiality in testing including:
 - (a) A testing laboratory may not offer a different fee schedule or waive payment in the event of failing or otherwise undesirable test results; and
 - (b) Refunds, rebates or any other return of payment in the form of alternate compensation is not permitted for the reason of failing or otherwise undesirable test results.
3. A cannabis independent testing laboratory is not required to use a cannabis distributor to collect or move samples for testing.
- 4. A cannabis independent testing laboratory shall implement a safety program which meets all applicable requirements of Laboratory Safety Guidance published by the Occupational Safety and Health Administration of the United States Department of Labor.**

(Amended: 7/2022)

11.020 Agreement to become accredited within 1 year after licensure; provision of annual inspection report to Board; inspection by accrediting organization is not substitute for inspection by Board.

1. Each cannabis independent testing laboratory must agree to become accredited pursuant to standard ISO/IEC 17025 of the International Organization for Standardization within 1 year after licensure. The scope of accreditation must cover all analytes pursuant to NCCR 11.050.
2. Each cannabis independent testing laboratory that claims to be accredited must provide the Board with copies of each annual inspection report from the accrediting organization, including, without limitation, any deficiencies identified in and any corrections made in response to the report. **The final inspection report and accreditation certificate must be provided to the Board within 2 business days of receipt.**
3. Inspection by an accrediting organization is not a substitute for inspection by the Board or Board Agents.

11.025 Adherence to general laboratory standards, practices, procedures and programs; inspection by Board or authorized third party; adoption of publications by reference.

1. Each cannabis independent testing laboratory must:
 - ~~(a) Follow the most current version of the Cannabis Inflorescence: Standards of Identity, Analysis, and Quality Control monograph published by the American Herbal Pharmacopoeia.~~
 - ~~(b) Follow the Recommendations for Regulators—Cannabis Operations published by the American Herbal Products Association.~~
 - ~~(e)~~ *(a)* Be accredited pursuant to standard ISO/IEC 17025 of the International Organization for Standardization by an impartial organization that operates in conformance with standard ISO/IEC 17011 of the International Organization for Standardization and is a signatory to the Mutual Recognition Arrangement of the International Laboratory Accreditation Cooperation.
 - ~~(d)~~ *(b)* Follow *Adhere to* the Guidelines for Laboratories Performing Microbiological and Chemical Analyses of Food, Dietary Supplements, and Pharmaceuticals — An Aid to the Interpretation of ISO/IEC 17025:2005 (2015) 2017 published by AOAC International. *Upon publication of the cannabis appendix, the Board may require an accreditation pursuant to this standard.*
 - (c)* *Adhere to ASTM D8282: “Standard Practice for Laboratory Test Method Validation and Method Development”, published by the American Society for Testing and Materials (ASTM).*
 - (d)* *Adhere to ASTM D8347 21a: “Standard Guide for Requirements for Analytical Laboratory Related Professions Within the Cannabis and Hemp Industries”, published by the American Society for Testing and Materials (ASTM).*
 - (e)* *Adhere to ASTM D8244-20: “Standard Guide for Analytical Operations Supporting the Cannabis Industry”, published by the American Society for Testing and Materials (ASTM).*
 - (f)* *Adhere to ASTM D8334/D8334M-20 Standard Practice for Sampling of Cannabis/Hemp Post-Harvest Batches for Laboratory, published by the American Society for Testing and Materials (ASTM).*
2. Each cannabis independent testing laboratory shall demonstrate proficiency in testing samples using the analytical methods approved by the Board or the appropriate Board Agent by participating in the approved proficiency testing program for all required analytes within 6 months after the date upon which the cannabis independent testing laboratory is issued a license.
3. The Board may require an independent third party to inspect and/or monitor the analytical testing methodologies and technical competence of the cannabis independent testing laboratory on an ongoing basis.
4. Each cannabis independent testing laboratory shall:
 - (a) Adopt and follow minimum good laboratory practices which must, at a minimum, satisfy the OECD Series on Principles of Good Laboratory Practice (GLP) and Compliance Monitoring published by the Organisation for Economic Co-operation and Development.
 - (b) Become certified by the International Organization for Standardization and agree to have the inspections and reports of the International Organization for Standardization made available to the Board or Board Agents.
 - (c) Maintain internal standard operating procedures. A copy of these procedures shall be provided promptly to the Board or Board Agents upon request.

- (d) Maintain a quality control and quality assurance program. *The quality assurance program must include a written ethics policy, provide training to all laboratory staff on the ethics policy, and require all laboratory staff to sign an attestation statement that they will adhere to the ethics policy.*
5. The Board Agents or an independent third party authorized by the Board may conduct an inspection of the practices, procedures and programs adopted, followed and maintained pursuant to subsection 4 and inspect all records of the cannabis independent testing laboratory.
6. A cannabis independent testing laboratory must use, when available, testing methods that have undergone validation by the Official Methods of Analysis of AOAC International, *or the Performance Tested Methods Program of the Research Institute of AOAC International.* *If these are not available, the cannabis independent testing laboratory may use methodologies from* the Bacteriological Analytical Manual of the Food and Drug Administration, the International Organization for Standardization, the United States Pharmacopeia, the Microbiology Laboratory Guidebook of the Food Safety and Inspection Service of the United States Department of Agriculture, *the Elemental Analysis Manual for Food and Related Products of the Food and Drug Administrations, the Pesticide Analytical Manual of the Food and Drug Administration,* or an equivalent third-party validation study approved by the Board. If no such testing method is available, a cannabis independent testing laboratory may use an alternative testing method or a testing method developed by the cannabis independent testing laboratory upon demonstrating the validity of the testing method *in cannabis matrices and* receiving the approval of the *appropriate Board Agent.*
7. All quality assurance tests pursuant to NCCR 11.050 *shall meet the AOAC Cannabis Standard Method Performance Requirements (SMPRs) for the adopted reference method, at a minimum, and* shall be validated or verified *according to, as applicable:* ~~by the cannabis independent testing laboratory observing the guidelines of the most recent version of standard~~
- (a) ASTM D8282: “Standard Practice for Laboratory Test Method Validation and Method Development”, published by the American Society for Testing and Materials (ASTM), and available at www.astm.org., or any subsequent standard as approved by the appropriate Board Agent.*
 - (b) AOAC - Appendix J: Guidelines for Validation of Microbiological Methods for Food and Environmental Surfaces, 2012;*
 - (c) AOAC - Appendix K: Guidelines for Dietary Supplements and Botanicals, 2013;*
 - (d) Standard ISO/IEC 16140-3 “Microbiology of the Food Chain- Method Validation-Part 3: Protocol for the verification of reference methods and validated alternative methods in a single laboratory”;* *or,*
 - (e) Any subsequent standard as approved by the appropriate Board Agent.*

8. The Board hereby adopts by reference:

(a) Recommendations for Regulators — Cannabis Operations published by the American Herbal Products Association.

~~(a) (b)~~ The Cannabis Inflorescence: Standards of Identity, Analysis, and Quality Control monograph published by the American Herbal Pharmacopoeia. A copy of that publication may be obtained from the American Herbal Pharmacopoeia, P.O. Box 66809, Scotts Valley, California 95067, ~~or at the Internet address <http://www.herbal-ahp.org/>;~~

~~(b) (c)~~ The current version of the OECD Series on Principles of Good Laboratory Practice (GLP) and Compliance Monitoring published by the Organisation for Economic Co-operation and Development. ~~A copy of that publication may be obtained free of charge from the Organisation for Economic Co-operation and Development at the Internet address <http://www.oecd.org/env/chs/testing/oecdseriesonprinciplesofgoodlaboratorypracticeglpandcompliancemonitoring.htm>;~~

~~(c) (d)~~ Standard ISO/IEC 17025 published by the International Organization for Standardization. ~~A copy of that publication may be obtained from the American National Standards Institute at the Internet address <https://webstore.ansi.org/RecordDetail.aspx?sku=ISO%2fIEC+17025%3a2005> <https://webstore.ansi.org/Standards/ISO/isoiec170252017>;~~

~~(d) (e)~~ The Guidelines for Laboratories Performing Microbiological and Chemical Analyses of Food, Dietary Supplements, and Pharmaceuticals — An Aid to the Interpretation of ISO/IEC 17025:2005 ~~(2015)~~ 2017 published by AOAC International. ~~A copy of that publication may be obtained from AOAC International at the Internet address <https://www.aoac.org/aoac-accreditation-guidelines-for-laboratories-alacc/>;~~

(f) WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fourth report. Geneva: World Health Organization; 2020 (WHO technical report series; no. 1025). Annex 4: Good Chromatography Practices;

(g) The OECD Guidance Document for Single Laboratory Validation of Quantitative Analytical Methods - Guidance Used in Support of Pre-And-Post-Registration Data Requirements for Plant Protection and Biocidal Products published by the Organisation for Economic Co-operation and Development;
and

(h) BOTEC Analysis--Sampling Cannabis for Analytical Purposes: Evidence Review and Best Practices(2023); and

(i) Upon its publication, the Board may adopt the Cannabis Regulators Association (CANNRA) Laboratory Testing and Standardization Guidance as a reference.

11.030 Establishment of policies for adequate chain of custody and requirements for samples of products provided to testing laboratory. Each cannabis independent testing laboratory must establish and follow policies for an adequate chain of custody and sample identification requirements for samples of products provided to the cannabis independent testing laboratory for testing or research purposes, including, without limitation, policies and requirements for:

1. Issuing instructions for the minimum sample and storage requirements;
- ~~2.~~ 2. Ensuring positive identification of the cannabis or cannabis product by verifying the accuracy of the seed-to-sale tracking information present on the source package immediately prior to sample collection. Laboratory staff must verify the Metrc tag matches the transfer manifest and laboratory Chain of Custody.
- ~~2.~~ 3. Documenting the condition of the external package and integrity seals utilized to prevent contamination of, or tampering with, the sample on the laboratory chain of custody document and/or the seed-to-sale transfer manifest;
- ~~3.~~ 4. Documenting the condition and amount of the sample provided at the time of collection or receipt on the laboratory chain of custody document and/or the seed-to-sale transfer manifest;
- ~~4.~~ 5. Documentation of any pertinent sample identifiers, including but not limited to product type, product name, strain name, seed-to-sale tracking number, batch/lot number and production run number as appropriate;
- ~~5.~~ 6. Documenting all persons handling the original samples, aliquots and extracts;
- ~~6.~~ 7. Providing adequate identification on sample containers throughout all phases of testing, including, but not limited to aliquots, dilutions, tubes, slides, culture plates, extracts, data files, images, and other secondary samples created during the processing or testing of a sample. The sample identifier(s) on any sample container must be indelible, legible, and able to withstand all stages of processing and conditions of storage;
- ~~7.~~ 8. Documenting all transfers of samples, aliquots and extracts referred to another cannabis independent testing laboratory for additional testing or whenever requested by a client;
- ~~8.~~ 9. Maintaining a current list of authorized cannabis establishment agents and restricting entry to the laboratory to only those authorized;
- ~~9.~~ 10. Securing the cannabis independent testing laboratory during nonworking hours;
- ~~10.~~ 11. Securing short- and long-term storage areas when not in use;
- ~~11.~~ 12. Utilizing a secured area to log-in and aliquot samples;
- ~~12.~~ 13. Ensuring samples are stored appropriately; and
- ~~13.~~ 14. Documenting the disposal of samples, aliquots and extracts- and
- ~~14.~~ 15. Follow, at a minimum, the chain of custody and sample identification requirements of ASTM D8334/D8334M-20 Standard Practice for Sampling of Cannabis/Hemp Post-Harvest Batches for Laboratory Analyses, for all cannabis products.

11.045 Limited testing for research and development purposes.

1. A cannabis cultivation facility or a cannabis production facility may conduct operations and request limited laboratory testing by a cannabis independent testing laboratory for research and development purposes.

2. A cannabis cultivation facility or cannabis production facility described in subsection 1 shall:

(a) Notify, and receive approval from, the appropriate Board Agent of its intent to conduct research and development on a form prescribed by the Board by electronic mail before sending a sample to a cannabis independent testing laboratory;

~~(b) Receive approval from the appropriate Board Agent for the requested research and development studies.~~

~~(c)~~ (b) Quarantine each batch, lot or production run in a separate quarantine area and label each batch, lot or production run with a distinctive label containing “R&D QUARANTINE” as a header and footer in at least 20-point white font and a red background;

~~(d)~~ (c) Account for all cannabis subject to quarantine pursuant to paragraph (b) in the seed-to-sale tracking system;

~~(e)~~ (d) Limit all research and development operations to clearly segregated and designated areas or rooms marked “R&D CULTIVATION AREA” or “R&D PRODUCTION AREA” on at least 8 1/2 by 11-inch signs with a red background and white lettering, posted at the entrance to the area or room and along the walls of the area or room, with a minimum of one sign for every 300 square feet of the area or room; and

~~(f)~~ (e) Perform research and development operations in a grow room only if the plants used for such operations are designated and separated from other plants.

(f) The cannabis cultivation facility or cannabis production facility must provide the research and development (R&D) approval form to the cannabis independent testing laboratory that will be performing the R&D testing laboratory prior to laboratory sample collection.

3. A cannabis cultivation facility or cannabis production facility operating as described in subsection 1 may request limited testing protocols from a cannabis independent testing laboratory for research and development purposes. A cannabis independent testing laboratory shall not perform any laboratory tests on research and development samples which were not specifically indicated as part of the approved study.

(a) The Board may draft a policy allowing licensees to apply for a variance on testing requirements under certain conditions for R&D purposes.

4. A cannabis independent testing laboratory that performs testing for a cannabis cultivation facility or cannabis production facility described in subsection 1 shall report the results of the testing to the cannabis establishment and to the Board ~~by electronic mail~~ in a manner prescribed by the Board. The cannabis independent testing laboratory shall clearly mark the test results with “R&D TESTING ONLY -- NOT FOR RESALE” on the top of each page of the report in 20-point white font and a red background.

5. A batch, lot or production run produced for research and development purposes pursuant to this section which fails quality assurance testing need not be destroyed.

6. A batch, lot or production run originally produced for research and development purposes pursuant to this section may not be sold to a cannabis sales facility until the batch, lot or production run has undergone and passed all testing required by NCCR 6.100. The cultivation or production facility must utilize the same cannabis independent testing laboratory who performed the limited testing on a lot or production run in accordance with subsection 3 to perform the final testing of that lot or production run.

7. A batch, lot or production run which fails quality assurance testing under research and development provisions may not be remediated without Board approval.

11.050 Required quality assurance tests; submission of wet cannabis for testing.

1. Each cannabis independent testing laboratory must use the sampling protocols and the general body of required quality assurance tests for usable cannabis, as received, concentrated cannabis and cannabis products set forth in this section. Such tests may include moisture content, potency analysis, foreign matter inspection, microbial screening, pesticide and other chemical residue and metals screening and residual solvents levels. A cannabis independent testing laboratory may request permission from the appropriate Board Agent to obtain additional sample material for the purposes of completing required quality assurance tests but may not use such material for the purposes of resampling or repeating quality assurance tests. A cannabis independent testing laboratory may retrieve samples from the premises of another cannabis establishment and transport the samples directly to the cannabis independent testing laboratory. A cannabis independent testing laboratory transporting samples may make multiple stops if:

- (a) Each stop is for the sole purpose of retrieving a sample from a cannabis establishment; and
- (b) All samples remain secured at all times.

///

///

///

///

///

///

2. The tests required pursuant to subsection 1 by a cannabis independent testing laboratory are as follows:

Product	Tests Required	Action Levels
Usable cannabis, infused pre- and crude collected resins, received, excluding wet cannabis	<ol style="list-style-type: none"> 1. Moisture content 2. Potency analysis 3. Terpene analysis 4. Foreign matter inspection 5. Mycotoxin screening 6. Heavy metal screening 7. Pesticide residue analysis 8. Herbicide screening 9. Growth regulator screening 10. Total yeast and mold 11. Total Enterobacteriaceae 12. Salmonella 13. Pathogenic E. coli 14. Aspergillus fumigatus 15. Aspergillus flavus 16. Aspergillus terreus 17. Aspergillus niger 18. Total coliform 	<ol style="list-style-type: none"> 1. < 15% 2. N/A 3. N/A 4. None detected 5. < 20 ug/kg for the total of Aflatoxins B1, B2, G1 and G2 combined and < 20 ug/kg for Ochratoxin A 6. Arsenic: < 2 ppm Cadmium: < 0.82 ppm Lead: < 1.2 ppm Mercury: < 0.4 ppm 7. See NAC 555.650 NCCR 11.065 8. See NAC 555.650 NCCR 11.065 9. See NAC 555.650 NCCR 11.065 10. < 10,000 colony forming units per gram 11. < 1,000 colony forming units per gram 12. None detected per gram 13. None detected per gram 14. None detected per gram 15. None detected per gram 16. None detected per gram 17. None detected per gram 18. < 1,000 colony forming units per gram
<u>Usable cannabis, as received, which is destined for extraction</u>	<ol style="list-style-type: none"> <u>1. Foreign matter inspection</u> <u>2. Mycotoxin screening</u> <u>3. Heavy metal screening</u> <u>4. Pesticide residue analysis</u> <u>5. Herbicide screening</u> <u>6. Growth regulator screening</u> <u>7. Total Enterobacteriaceae</u> <u>8. Salmonella</u> <u>9. Pathogenic E. coli</u> 	<ol style="list-style-type: none"> <u>1. None detected</u> <u>2. < 20 ug/kg for the total of Aflatoxins B1, B2, G1 and G2 combined and < 20 ug/kg for Ochratoxin A</u> <u>3. Arsenic: < 2ppm Cadmium: <0.82 ppm Lead: 1.2 ppm Mercury: < 0.4 ppm</u> <u>4. See NCCR 11.065</u> <u>5. See NCCR 11.065</u> <u>6. See NCCR 11.065</u> <u>7. < 1,000 colony forming units per gram</u> <u>8. None detected per gram</u> <u>9. None detected per gram</u>

Product	Tests Required	Action Levels
Wet cannabis, as received, which is destined for extraction	1. Potency analysis 2. Terpene analysis 3. 1. Foreign matter inspection 4. 2. Mycotoxin screening 5. 3. Heavy metal screening 6. 4. Pesticide residue analysis 7. 5. Herbicide screening 8. 6. Growth regulator screening 9. Total yeast and mold 10. 7. Total Enterobacteriaceae 11. 8. Salmonella 12. 9. Pathogenic E. coli 13. Aspergillus fumigatus 14. Aspergillus flavus 15. Aspergillus terreus 16. Aspergillus niger 17. Total coliform	1. N/A 2. N/A 3. 1. None detected 4. 2. < 20 µg/kg for the total of Aflatoxins B1, B2, G1 and G2 combined and < 20 µg/kg for Ochratoxin A 5. 3. Arsenic: < 2 ppm Cadmium: < 0.82 ppm Lead: < 1.2 ppm Mercury: < 0.4 ppm 6. 4. See NCCR 11.065 7. 5. See NCCR 11.065 8. 6. See NCCR 11.065 9. < 10,000 colony forming units per gram 10. 7. < 1,000 colony forming units per gram 11. 8. None detected per gram 12. 9. None detected per gram 13. None detected per gram 14. None detected per gram 15. None detected per gram 16. None detected per gram 17. < 1,000 colony forming units per gram
Extract of cannabis (nonsolvent) like hashish, bubble hash, infused dairy butter, mixtures of extracted products or oils or fats derived from natural sources, including concentrated cannabis extracted with ethanol or CO2	1. Potency analysis 2. Foreign matter inspection 3. Mycotoxin screening 4. Heavy metal screening 5. Pesticide residue analysis 6. Total yeast and mold 7. Total Enterobacteriaceae 8. Salmonella 9. Pathogenic E. coli 10. Aspergillus fumigatus 11. Aspergillus flavus 12. Aspergillus terreus 13. Aspergillus niger	1. N/A 2. None detected 3. < 20 µg/kg for the total of Aflatoxins B1, B2, G1 and G2 combined and < 20 µg/kg for Ochratoxin A 4. Arsenic: < 2 ppm Cadmium: < 0.82 ppm Lead: < 1.2 ppm Mercury: < 0.4 ppm 5. See NCCR 11.065 6. < 1,000 colony forming units per gram 7. < 100 colony forming units per gram 8. None detected per gram 9. None detected per gram 10. None detected per gram 11. None detected per gram 12. None detected per gram 13. None detected per gram

Product	Tests Required	Action Levels
<p>Extract of cannabis (solvent-based) made with any approved solvent, Including concentrated cannabis extracted by means other than with ethanol or CO2</p>	<ol style="list-style-type: none"> 1. Potency analysis 2. Foreign matter inspection 3. Residual solvent test 4. Mycotoxin screening 5. Heavy metal screening 6. Pesticide residue analysis 7. Total yeast and mold 8. Total Enterobacteriaceae 9. Salmonella 10. Pathogenic E. coli 11. Aspergillus fumigatus 12. Aspergillus flavus 13. Aspergillus terreus 14. Aspergillus niger 	<ol style="list-style-type: none"> 1. N/A 2. None detected 3. < 500 ppm 4. < 20 µg/kg for the total of Aflatoxins B1, B2, G1 and G2 combined and < 20 µg/kg for Ochratoxin A 5. Arsenic: < 2 ppm Cadmium: < 0.82 ppm Lead: < 1.2 ppm Mercury: < 0.4 ppm 6. See NCCR 11.065 7. < 1,000 colony forming units per gram 8. < 100 colony forming units per gram 9. None detected per gram 10. None detected per gram 11. None detected per gram 12. None detected per gram 13. None detected per gram 14. None detected per gram
<p>Edible cannabis product, including a product which contains concentrated cannabis</p>	<ol style="list-style-type: none"> 1. Potency analysis 2. Foreign matter inspection 3. Total Enterobacteriaceae 4. Salmonella 5. Pathogenic E. coli 6. Total aerobic count 7. Water activity or pH 	<ol style="list-style-type: none"> 1. N/A 2. None detected 3. < 1,000 colony forming units per gram 4. None detected per gram 5. None detected per gram 6. < 100,000 colony forming units per gram 7. Water activity < 0.86 or pH < 4.6
<p>Liquid cannabis product, including, without limitation, soda or tonic, including a product which contains concentrated cannabis</p>	<ol style="list-style-type: none"> 1. Potency analysis 2. Foreign matter inspection 3. Total Enterobacteriaceae 4. Salmonella 5. Pathogenic E. coli 6. Total aerobic count 7. Water activity or pH 	<ol style="list-style-type: none"> 1. N/A 2. None detected 3. < 1,000 colony forming units per gram 4. None detected per gram 5. None detected per gram 6. < 100,000 colony forming units per gram 7. Water activity < 0.86 or pH < 4.6
<p>Topical cannabis product, including a product which contains concentrated cannabis</p>	<ol style="list-style-type: none"> 1. Potency analysis 	<ol style="list-style-type: none"> 1. N/A

3. A sample of usable cannabis must be at least ~~10~~ *20 grams*. A sample of a production run must be the lesser of 1 percent of the total product weight of the production run or 25 units of product, but not less than 5 grams of the production run. Before testing, all samples must be homogenized by the testing laboratory using a homogenization process which has been approved by the appropriate Board Agent and in a manner that prevents contamination of test samples or analytical portions.
4. The analytical portion that is used for the purposes of ~~any~~ *each* microbial test must be a minimum of one gram, unless otherwise approved by the Board.
5. A cannabis establishment shall not submit wet cannabis to a cannabis independent testing laboratory for testing unless the wet cannabis is destined for extraction and weighed within 2 hours after harvest. The plant must not undergo any further processing, including, without limitation, drying the plant and subsequently selling separately the cannabis bud and cannabis trim from the plant, before being weighed.
6. As used in this section, “as received” means the unaltered state in which a sample was collected, without any processing or conditioning, which accounts for all mass, including moisture content. A cannabis independent testing laboratory shall not report the results of usable cannabis on a dry weight basis.
7. A cannabis independent testing laboratory shall ~~provide~~ *make available* the final certificate of analysis to the Board *upon request* ~~and to the cannabis establishment from which the sample was collected~~ within 2 business days after obtaining the results.
8. The certificate of analysis shall include a photo of the product, as received.
- 9. The certificate of analysis shall include the statement, in 8-point font, “The test results listed in this COA may not reflect the current state of the product if more than one year old, due to product changes during storage.”*

11.053 Requirements for instrument calibration and quality control.

1. A cannabis independent testing laboratory shall ensure that all instruments and equipment used for testing cannabis and cannabis products are:

(a) Set up, tuned, and calibrated according to the laboratory's validated methods; and

(b) Applicable for the analytes to be tested.

2. A cannabis independent testing laboratory meet the following requirements related to calibration and standards:

(a) A minimum of:

(1) Five standards shall be used for an average response factor or for a linear model;

(2) Six standards shall be used for a quadratic model.

(b) The calibration curve must not be forced through the origin;

(c) At least one calibration standard shall be at or below the limit of quantitation;

(d) One standard for each analyte shall be at or near the State action level, where State action levels are applicable commensurate with the dilution level of the method;

(e) One calibration standard must be a mid-level standard at 50% of the calibration range;

(f) A minimum of one calibration standard must be between the mid-level standard and highest-level standard (have a concentration 50-100% of the range of the calibration curve);

(g) The correlation coefficient (r) for standard concentration to instrument response is greater than or equal to 0.995;

3. A cannabis independent testing laboratory may not:

(a) Remove data points from within a calibration range while still retaining the extreme ends of the calibration range.

(b) Use non-linear calibrations to compensate for detector saturation or to avoid proper instrument maintenance.

(c) Apply a calibration fit which was not validated for that method.

4. For test methods using internal standards for calibration, the following requirements must be met:

(a) For chromatographic methods, internal standards must:

(1) Have retention times similar to the analytes being tested for;

(2) Not interfere with any of the analytes; and

(3) Have similar chemical properties as the analytes being tested for.

(b) For heavy metals testing, the internal standards must:

(1) Be appropriate for the analyte and the instrumental method used; and

(2) Not interfere with any of the analytes.

5. A cannabis independent testing laboratory shall implement and adhere to the following quality control (QC) practices:

(a) Initial calibration verification:

- (1) Must be prepared from a different source than that from which the initial calibration standards were obtained or from a different lot of standards from the same source; and
- (2) Must be run at the beginning of the analytical sequence.

(b) Continuing calibration verification:

- (1) Must be prepared from the same source calibration standard used to prepare the calibration curve; and
- (2) Shall be included in an analytical batch at the following frequency, at minimum:
- (3) After every 20 injections and
- (4) At the end of the analytical sequence.

(c) The following acceptance criteria shall not be exceeded for calibration verification samples, both initial and continuing:

- (1) For cannabinoids testing, 80% - 120% recovery of the true value.
- (2) For terpenes testing, 75%-125% recovery of the true values
- (3) For pesticides, herbicides, and plant growth regulators testing, 75% - 125% recovery of the true value.
- (4) For residual solvents testing, 75% - 125% recovery of the true value.
- (5) For heavy metals testing, 90% - 110% recovery of the true value.
- (6) More stringent criteria shall be used where required by a specific analytical method.

(d) An independent testing laboratory may not report sample results which are associated with QC that have exceeded the tolerance limits specified in this section.

11.060 Performance of testing to verify homogeneity of potency of edible cannabis products.

1. Except as otherwise provided in subsection 2, a cannabis independent testing laboratory shall perform testing to verify the homogeneity of the potency of an edible cannabis product by testing multiple samples from a single production run.

2. A cannabis independent testing laboratory that tests an edible cannabis product which has previously had the homogeneity of the potency of the edible cannabis product verified by a cannabis independent testing laboratory and which has not undergone a change in recipe may verify the homogeneity of the edible cannabis product by testing one or more single units or servings from a production run of the edible cannabis product.

3. The cannabis independent testing laboratory will verify the homogeneity of the potency of the edible cannabis product only if:

- (a) The concentration of THC ~~and weight~~ of each sample is within 15 percent above or below the intended concentration of THC ~~and weight~~; and
- (b) ~~No combination of samples which comprise 10 percent or less of the cannabis product contain 20 percent or more of the total THC in the cannabis product.~~ The concentration of THC of each sample must not exceed the intended THC limits for sale in NCCR 9.045 section 2.

11.065 Use of approved pesticides by cannabis establishment; performance of pesticide residue analysis by testing laboratory.

1. A cannabis establishment shall only use a pesticide in the cultivation or production of cannabis or cannabis products if the pesticide appears on the list of pesticides published by the State Department of Agriculture pursuant to NRS 586.550.
2. When performing pesticide residue analysis pursuant to NCCR 11.050, a cannabis independent testing laboratory shall analyze for the pesticides which occur on the list of pesticides published by the State Department of Agriculture pursuant to NRS 586.550 at the detection levels specified by the State Department of Agriculture and for any other substances required by the Board. If:
 - (a) A pesticide which occurs on the list of pesticides published by the State Department of Agriculture pursuant to NRS 586.550 is detected at a level which exceeds the level specified by the State Department of Agriculture; or
 - (b) A pesticide which does not occur on the list of pesticides published by the State Department of Agriculture pursuant to NRS 586.550 is detected in any amount which is positively ~~verified~~ identified by the cannabis independent testing laboratory equal to, or greater than, the limit of detection established by the laboratory, the pesticide residue analysis is failed.
 - (c) Limits of detection must be defined for every pesticide analyzed by the laboratory and must be lower than the limits of quantitation.

11.070 Testing: Selection of representative samples and random samples; segregation period for entire lot; duties of testing laboratory; disposal of lot if sample fails test; release of lot if sample passes test; filing of electronic copy of certificate of analysis for tests performed by testing laboratory; grounds for disciplinary action for failure to comply.

1. Immediately before packaging:
 - (a) Usable cannabis for sale to a cannabis sales facility, cannabis production facility or another cannabis cultivation facility, a cannabis cultivation facility shall segregate all harvested cannabis into homogenized lots of flower and trim, respectively, and allow a cannabis independent testing laboratory to select a homogenous representative sample for testing from each lot the cannabis cultivation facility has segregated. The cannabis testing laboratory which performs the test must collect the samples. If the cannabis cultivation facility has segregated the lot of harvested cannabis into packages or container sizes smaller than the entire lot, the cannabis cultivation facility must present all packages comprising the lot to the cannabis independent testing laboratory, and the testing laboratory must sample and test each package containing harvested cannabis from the lot.
 - (b) Concentrated cannabis or cannabis products, a cannabis production facility shall segregate concentrated cannabis or cannabis products into production runs and allow a cannabis independent testing laboratory to randomly select a ~~random~~ homogeneous representative sample for testing from each ~~lot or~~ production run ~~for testing by the cannabis independent testing laboratory~~. The cannabis independent testing laboratory performing the testing must collect the samples. If a production run of concentrated cannabis or cannabis products is stored in multiple containers, the cannabis production facility must present all containers comprising the production run to the cannabis independent testing laboratory, and the testing laboratory must sample and test each container which comprises the production run.

(1) The cannabis independent testing laboratory must follow ASTM D8334/D8334M-20 Standard Practice for Sampling of Cannabis/Hemp Post-Harvest Batches for Laboratory Analyses, including, but not limited to, the aseptic sampling procedures described below when collecting samples for testing.

(2) The laboratory must use aseptic sampling techniques when collecting all cannabis category types, and adhere to the steps described below, at a minimum:

(I) Fit-for-purpose sampling equipment such as tongs, spatulas, calipers, or sample corers must be used for sampling cannabis and cannabis products. The sampling equipment must be aseptically cleaned between the sampling of different lots or production runs (or more times, if determined necessary by the sample collector) using ethanol, minimum 70%, or equivalent.

(II) The sample collector will wear new aseptic gloves before sampling a different harvest batch or production run (or more frequently, if determined necessary by the sample collector).

(III) The sample aliquot(s) shall be taken from multiple areas of each container (i.e., the upper, middle, and lower sections), such that the samples taken are representative of the entire lot or production run. In the case of large bales or bags, samples must be taken from a depth of at least 10 cm [3.9 in.].

(IV) The sample collector shall take extreme care if sampling from multiple sites in one day to ensure contaminants (such as microorganisms, insects, residues, etc.), pathogens, or other organisms or substances are not transferred between facilities.

(V) The field balance used for sampling must meet the following requirements, at minimum:

(a) Must be capable of weighing 65 % of specimen weight or 0.1 g [0.000220462 lb], whichever is less.

(b) Must be calibrated to include the range of specimen weight.

- (c) The cannabis independent testing laboratory selecting a sample shall seal the sample within the package to ensure sample integrity. The sample shall be collected in a tamper resistant package or in a package that is sealed with tamper resistant tape immediately after the sample is placed in the package.
- (d) The cannabis independent testing laboratory shall ensure the seed-to-sale identification tag is affixed to the sample package. The batch, lot or production run number and the weight or quantity of the sample shall be documented on the sample package and on the chain of custody.
2. A cannabis independent testing laboratory that collects a sample pursuant to this section shall test the sample as provided in NCCR 11.050.
3. From the time that a lot or production run has been homogenized for sample testing and eventual packaging and sale to a cannabis sales facility, cannabis production facility or, if applicable, another cannabis cultivation facility, the cannabis establishment which provided the sample shall segregate and withhold from use the entire lot or production run, except the samples that have been removed by the cannabis independent testing laboratory for testing, until the cannabis independent testing laboratory provides the certificate of analysis from its tests and analysis. During this period of segregation, the cannabis establishment which provided the sample shall maintain the lot or production run in a secure, clearly designated,

cool and dry location so as to prevent the cannabis from becoming contaminated or losing its efficacy. Under no circumstances shall the cannabis establishment which provided the sample sell the cannabis or cannabis products, as applicable, to a cannabis sales facility, cannabis production facility or, if applicable, another cannabis cultivation facility before the time that the cannabis independent testing laboratory has completed its testing and analysis and provided the certificate of analysis to the cannabis establishment which provided the sample.

~~4. Except as otherwise provided in subsection 5, a cannabis independent testing laboratory shall immediately return or dispose of any sample received pursuant to this section upon the completion of any testing, use or research. If a cannabis independent testing laboratory disposes of a sample received pursuant to this section, the cannabis independent testing laboratory shall document the disposal of the sample using its seed-to-sale tracking system pursuant to NCCR 6.080 and 6.082.~~

~~(5.)~~ **4.** A cannabis independent testing laboratory shall keep ~~any~~ **all** samples ~~which fails testing, or which is collected by the Board for confirmation testing~~ for 30 days after ~~failure or collection.~~ **testing.** A sample which is kept pursuant to this subsection must be stored in a manner approved by the appropriate Board Agent. A cannabis independent testing laboratory shall dispose of a sample kept pursuant to this subsection after 30 days have elapsed after ~~failure or collection.~~ **testing, use, or research, and shall document the disposal of the sample using its seed-to-sale tracking system pursuant to NCCR 6.080 and 6.082.**

~~6.~~ **5.** Except as otherwise provided in NCCR 11.075, if a sample provided to a cannabis independent testing laboratory pursuant to this section does not pass the testing required by NCCR 11.050, the cannabis establishment which provided the sample shall dispose of the entire lot or production run from which the sample was taken and document the disposal of the sample using its inventory control system pursuant to NCCR 6.080 and 6.082.

~~7.~~ **6.** If a sample provided to a cannabis independent testing laboratory pursuant to this section passes the testing required by NCCR 11.050, the cannabis independent testing laboratory shall release the entire lot or production run for immediate manufacturing, packaging and labeling for sale to a cannabis sales facility, a cannabis production facility or, if applicable, another cannabis cultivation facility.

~~8.~~ **7.** A cannabis establishment shall not use more than one cannabis independent testing laboratory to test the same lot or production run of cannabis without the approval of the appropriate Board Agent.

~~9.~~ **8.** A cannabis independent testing laboratory shall file with the Board, in a manner prescribed by the Board, an electronic copy of the certificate of analysis for all tests performed by the cannabis independent testing laboratory, regardless of the outcome of the test, including all testing required by NCCR 11.050 to 11.065, inclusive, ~~at the same time that it transmits those results to the facility which provided the sample.~~ **The cannabis independent testing laboratory shall not provide preliminary test results to a cannabis cultivation facility or cannabis production facility, including any of their employees or representatives, prior to submitting the Certificate of Analysis to the Board.** ~~The cannabis independent testing laboratory shall transmit an electronic copy of the certificate of analysis for each test to the Board by electronic mail at:~~

~~(a) If the test was passed, cannabislabpass@ceb.nv.gov; or~~

~~(b) If the test was failed, cannabislabfail@ceb.nv.gov.~~

~~10.~~ **9.** ~~An electronic mail message transmitted pursuant to subsection 9 must be formatted as follows:~~ **Certificates of Analysis must be reported as follows:**

~~(a) The subject line of the electronic mail message must be the name of the cannabis establishment from which the sample was collected. Test results and Certificate of Analysis must be uploaded to the seed-to-sale system.~~

(b) The name of the electronic file containing the certificate of analysis must be:

(1) Except as otherwise provided in subparagraph (2) or (3), the ~~Facility~~ cannabis establishment ID assigned by the Board to the cannabis independent testing laboratory, followed by an underscore, followed by the ~~four digit identifier~~ cannabis establishment ID assigned by the Board to the cannabis establishment from which the sample was collected, followed by an underscore, followed by the identification number assigned to the test sample within the seed-to-sale tracking system. Followed by an underscore, followed by the product name assigned to the test sample within the seed-to-sale tracking system. :

~~(I) If the sample was from a production run, the production run number; or~~

~~(II) If the sample was not from a production run, the batch number, followed by an underscore, followed by the lot number.~~

(2) If the certificate of analysis is from a retesting of a previously failed sample, an underscore followed by the word “Retest” must be appended to the end of the name of the electronic file.

(3) If the certificate of analysis has been amended, an underscore followed by the word “Amended” must be appended to the end of the name of the electronic file.

(c) If the certificate of analysis has been amended, the electronic copy of the certificate of analysis must state “Amended” in 20-point bold red font at the center of the top of the first page of the report and must contain a statement of the reason for the amendment that clearly and completely describes the change in 10-point *red* font. The original laboratory results and Certificate of Analysis must be preserved by the testing laboratory for review by Board Agents upon request.

(d) If the Certificate of Analysis is from a retesting of a previously failed sample, the electronic copy of the certificate of analysis must state “Retest” in 20-point bold red font at the center of the top of the first page of the report. The original laboratory results and Certificate of Analysis must be preserved by the testing laboratory for review by Board Agents upon request.

~~11.~~ 10. The Board will take immediate disciplinary action against any cannabis establishment which fails to comply with the provisions of this section or falsifies records related to this section, including, without limitation, revoking the license of the cannabis establishment.

~~12.~~ 11. A cannabis independent testing laboratory may subcontract its testing of cannabis or cannabis products only to another cannabis independent testing laboratory. The name and cannabis establishment ID of the cannabis testing laboratory which performed the subcontracted testing must be indicated on the final Certificate of Analysis in at least 8-point font.

~~13.~~ 12. The Board may publish on their website all Certificates of Analysis issued to them in the preceding time.

(Amended: 8/2021)

11.075 Testing: Authorized use of cannabis upon failure of microbial screening; automatic failure to pass; request for retest; retest for pesticide residue must be performed by State Department of Agriculture; effect of passing or failing retest.

1. Upon approval of the appropriate Board Agent, a lot or production run of cannabis that fails a residual solvent, pH, water activity (aw), homogeneity, or microbial screening test may be remediated or used to make an extract. After processing, the remediated lot or extract must pass all required quality assurance tests. Processes for treatment or remediation of cannabis must be pre-approved by the appropriate board agent.

(a) The cannabis establishment must maintain documentation of post-harvest treatment or remediated lots, including the date and method of treatment or remediation. All post-harvest treatment or remediation processes must be pre-approved by the appropriate Board agent.

2. If a sample from a cannabis production facility fails a quality assurance test, the entire production run from which the sample was taken automatically fails the quality assurance test.

3. At the request of a cannabis cultivation facility or a cannabis production facility, the appropriate Board Agent may, on a case-by-case basis, authorize a retest to validate the results of a failed test. The cannabis cultivation facility or cannabis production facility is responsible for all costs involved in a retest performed pursuant to this section.

4. A cannabis cultivation facility or a cannabis production facility may not request a retest pursuant to this section if the lot or production run has undergone any type of remediation since the time samples were initially taken for testing. *A cannabis independent testing laboratory may not retest a lot, production run or test sample of cannabis or cannabis products or implement internal retesting procedures for cannabis or cannabis products, without approval by the appropriate Board Agent.*

5. A cannabis cultivation facility or a cannabis production facility shall submit a request for retesting to the appropriate Board Agent in writing and on a form designated by the Board.

6. If the appropriate Board Agent grants a request for retesting, the Board Agent will select the cannabis independent testing laboratory that will perform the retest.

7. Except as otherwise provided in this subsection, a cannabis cultivation facility or a cannabis production facility may submit a request for retesting of not more than 50 lots or production runs each calendar year. For any subsequent failure of a quality assurance test in a calendar year, the facility shall request permission from the Board for an additional 50 tests, destroy the lot or the entire production run, or request to send the lot or production run to extraction or remediation. The Board may extend authority to the Executive Director of the CCB to approve such requests. If the additional 50 retests are approved, a cannabis cultivation facility or a cannabis production facility must obtain the results of two retests in the category which failed, from two different cannabis independent testing laboratories. For the retested lot or production run to be approved for sale, both retests must provide passing results. If both retests provide passing results, the certificate of analysis with the higher quantifiable results will be recorded. If it is not clear which certificate has higher results, the appropriate board agent will select the one to be recorded. No more than one such request for additional tests is permitted within a calendar year. A lot which only fails a quality assurance test for moisture content must not be counted for the purpose of this subsection.

(a) To request permission from the Board for an additional 50 tests, a cannabis cultivation facility or a cannabis production facility must file a petition with the Board which must include the following:

(1) Request for the additional 50 tests;

- (2) List the prior 50 lots or production runs that failed, what they failed for, and which cannabis independent testing laboratory performed the test; and
 - (3) List whether the prior 50 lots or production runs passed pursuant to a retest, and which cannabis independent testing laboratories performed the retests.
8. A failed quality assurance test for pesticide residue must be retested by the State Department of Agriculture unless otherwise approved by the Board or appropriate Board Agent.
9. If a sample passes the same quality assurance test upon retesting, the cannabis cultivation facility or cannabis production facility need not destroy the lot or production run and may sell the lot or production run to a cannabis cultivation facility, cannabis sales facility or cannabis production facility, as applicable.
10. If a sample fails the same quality assurance test upon retesting, the Board Agent denies a request for retesting or a cannabis cultivation facility or a cannabis production facility does not request retesting after a sample fails a quality assurance test, the facility shall destroy the entire lot or production run from which the sample was taken.

(Amended: 8/2021)

11.085 Random quality assurance compliance checks; costs for screening or testing.

1. Upon the request of the Board, a cannabis facility must provide a cannabis independent testing laboratory designated by the Board with a sample of cannabis or a cannabis product in an amount determined by the cannabis independent testing laboratory to be sufficient for random quality assurance compliance checks in a secure manner such that the cannabis independent testing laboratory can confirm that it has received and is testing the correct sample.
2. The cannabis independent testing laboratory that receives a sample pursuant to subsection 1 shall, as directed by the Board:
 - (a) Screen the sample for pesticides, chemical residues, herbicides, growth regulators and unsafe levels of metals;
 - (b) Perform any other quality assurance test deemed necessary by the Board; and
 - (c) Report its results to the Board.
3. ~~The responsibility cannabis cultivation facility or cannabis production facility is responsible~~ for all costs involved in screening or testing performed pursuant to this section. shall be borne in accordance with the following:
 - (a) If the testing is performed as a consequence of an investigation of a cannabis cultivation facility, the costs shall be borne by the cannabis cultivation facility even if the investigation does not lead to a substantiated violation of the law;
 - (b) If the testing is performed as a consequence of an investigation of a cannabis production facility, the costs shall be borne by the cannabis production facility even if the investigation does not lead to a substantiated violation of the law; or
 - (c) If the testing is performed as a consequence of an investigation of a cannabis independent testing laboratory, the costs shall be borne by the cannabis independent testing laboratory being investigated even if the investigation does not lead to a substantiated violation of the law.
4. A cannabis cultivation facility, cannabis production facility, or cannabis independent testing laboratory who is responsible for costs of testing pursuant to subsection 3 must remit payment for the costs to the cannabis independent testing laboratory that performed the testing within 30 days of receipt of the invoice.



JOE LOMBARDO
Governor

CANNABIS COMPLIANCE BOARD STATE OF NEVADA

ccb.nv.gov
CARSON CITY OFFICE
3850 Arrowhead Drive, Suite 100
Carson City, Nevada 89706
Main Line: (775) 687-6299

LAS VEGAS OFFICE
700 East Warm Springs Road, Suite 100
Las Vegas, Nevada 89119

JAMES HUMM
Executive Director

MICHAEL MILLES
Deputy Director

ADRIANA GUZMÁN FRALICK
Chair

SMALL BUSINESS IMPACT STATEMENT AS REQUIRED BY NRS 233.B.0608

Nevada Cannabis Compliance Regulations

1. Background

The Cannabis Compliance Board drafted proposed regulation changes to Nevada Cannabis Compliance Regulations (“NCCR”) 5, 7, and 11 to establish requirements relating to the inspections, certifications, and laboratory testing policies, procedures and guidelines, and to provide other matters properly relating thereto.

2. A description of the manner in which comments were solicited from affected small businesses, a summary of their responses, and an explanation of the manner in which other interested persons may obtain a copy of the summary.

On September 26, 2023, the Cannabis Compliance Board (“Agency”) held a workshop to gather input from the public for possible amendments to Nevada Cannabis Compliance Regulations (“NCCR”) 5, 7, and 11, and all public comment was considered.

On January 31, 2024, the Cannabis Compliance Board (“Agency”) held a meeting to gather Solicitation of Input from the public for possible amendments to Nevada Cannabis Compliance Regulations (“NCCR”) 1 through 15, and all public comment was considered.

On March 22, 2024, the Cannabis Compliance Board (“Agency”) notified the public of the proposed changes and upcoming workshop by posting a notice of workshop, proposed language, and survey on the CCB website.

Draft language provided proposed changes to the following NCCRs:

- Regulation 5. Licensing, Background Checks, and Registration Cards
- Regulation 7. Cannabis Sales Facility
- Regulation 11. Cannabis Independent Testing Lab

A twenty-eight-question survey solicited input and information from small businesses to gauge what impact proposed language would have on their businesses.

The survey and a link to the proposed language was distributed as follows:

- via Agency Listserv to 8,475 members of the public and members of the cannabis industry
- Posted on Agency and local chamber social media

The questionnaire was open for sixteen (16) days. During that time, 33 people completed the survey. Many of the respondents did not provide additional comments beyond indicating whether the regulations would have adverse or beneficial effects. Nongermane comments were omitted from the results.

Responses provided the following major themes:

- **Concerns on the impact of standardizing lab practices**
- **Desire for additional guidance regarding updates**
- **Desire for a mechanism for laboratories to recover debt owed by cultivators/producers for services rendered**

65% of respondents identified themselves as owners/officers.

84% of respondents identified themselves as affiliated with licensed cannabis establishments.

Other respondents identified as non-cannabis energy product producer (1 of 31), consultant (2 of 31), medical cannabis advocate (1 of 31), or did not identify an organization (1 of 31).

94% of respondents identified as having less than 150 employees but five respondents identified as non-cannabis establishments (consultants, medical cannabis advocates) or did not identify an organization.

26% of survey respondents indicated the proposed change to the regulations would result in direct **adverse** economic impact to their business.

13% of survey respondents indicated the proposed change to the regulations would result in direct **beneficial** impact to their business.

13% of survey respondents indicated the proposed change to the regulations would result in indirect **adverse** impact to their business.

10% of survey respondents indicated the proposed change to the regulations would result in indirect **beneficial** impact to their business.

Regulation 5 Adverse Impact

71% responded no or unsure/not affected 19% responded yes.

Explanations included:

- Concern that increased costs to labs will get passed on to the facilities and consumers
- Concern over increased bureaucracy
- Additional comments were not related to proposed regulation changes but related to Time and Effort billing charges which have been previously discontinued, how vertically integrated non-lab facilities get inspected, and excessive packaging

Regulation 5 Indirect Adverse Impact

94% answered no or unsure/not affected, 6% responded yes.

Explanations included:

- Concern over staffing requirements during a laboratory inspection **lab inspection team can work around staff absences, return for follow-up visits**
- Concern by non-lab facility over potential delay third-party vendor fulfilling orders

Regulation 5 Beneficial Impact

84 % responded no or unsure/not affected 16% responded yes

Explanations included:

- Beneficial impact to non-lab facilities of lower cost due to reduction in aspergillus testing
- Beneficial impact of reduced disruption of daily laboratory activities during inspection
- Additional comment was a perceived reduction in cost for a laboratory inspection due to fewer hours charged for Time and Effort billing, which has been previously discontinued

Regulation 5 Indirect Beneficial Impact

97% responded no or unsure/not affected, 3% responded yes

Explanations included:

- Indirect beneficial impact of increased confidence in laboratory testing leading to increased consumer confidence in the products sold in Nevada

Regulation 7 Adverse Impact

94% responded no or unsure/not affected 6% responded yes.

Explanations included:

- Comment not related to proposed regulation changes includes a desire for the CCB to allow dispensaries to sell full-hemp-derived products, including CBD tinctures and synthetic delta-8 concentrates

Regulation 7 Indirect Adverse Impact

97% answered no or unsure/not affected, 3% responded yes.

Explanations included:

- Comment not related to proposed regulation changes includes restrictions on sale of full-hemp-derived products will potentially send consumers to the unregulated market

Regulation 7 Beneficial Impact

97 % responded no or unsure/not affected 3% responded yes

Explanations included:

- Beneficial impact that heightened regulation will provide more confidence to the consumer

Regulation 7 Indirect Beneficial Impact

87 % responded no or unsure/not affected, 13% responded yes

Explanations included:

- Indirect beneficial impact of inspections providing increased confidence to consumers
- Indirect beneficial impact on consumers and cannabis brands by providing copies of COAs

Regulation 11 Adverse Impact

48% responded no or unsure/not affected 52% responded yes.

Explanations included:

- Concern that homogeneity testing changes could impact potency target values
- Concern that defining responsibility for payment in a lab investigation initiated by the CCB restricts the free market system
- Concern that ISO17025 and AOAC Guideline requirements conflict with the standardized documents added to the regulations **ISO17025 and AOAC Guidelines are the broad framework of quality systems with not much detail. Standardized documents/methods provide the details. There is no conflict. Proposed move towards standardized methods and documentations levels the playing field and reduces lab shopping. It was also at the request of the labs**
- Concern that geographic restriction on scientific director will reduce pool of candidates **Scientific director has full responsibility for the oversight of all lab activities, including a very comprehensive Quality Assurance program and complex tests and instrumentation. There is no substitute for their oversight and expertise. Two licensed labs that had long-distance directors have not fared well—one is permanently closed, the other currently suspended**
- Concern that changes to lab personnel requirements will reduce the pool of candidates **ASTM D8347 provides for a 3-year phase in training program until employee meets experience and body-of-knowledge requirements so minimal to no impact**
- Desire to keep the 90-day limit for interim director
- Desire to define deadlines as days rather than hours
- Concern that reduced testing requirements could impact the final product test result
- Concerns regarding impact of increasing the test sample size. **may need possible increase in storage capacity, depending on number of samples the lab receives**
- Concern about the impact of cannabis facilities bearing investigation costs **testing labs are doing this work for free even when the issue being investigated was not the testing lab's fault, facilities being investigated need to pay**
- Concern about impact of transition to standardized methods **labs currently use the same or similar methods/vendor kits as the new regs propose to make a requirement. Little to no change in cost, same or similar chemicals and supplies**
- Concern that removing required tests will require the laboratories to increase their prices per test to facilities
- Concern about the impact of implementing an OSHA lab safety standard **Lab safety is not currently addressed for Nevada cannabis labs. Hazardous chemicals are in use daily. The OSHA lab safety standard exists for employee safety, and it also protects against cross-contamination in the lab. All cannabis facility types (including labs) currently are required to have OSHA training for all employees, so this is not an unusual concept or requirement to them. Labs in every type of lab industry utilize OSHA lab safety rules**
- Explicit ethics requirement not needed, implicit in ISO 17025 requirement. **ethics requirement as proposed in the reg changes is standard-of-care in every regulated lab industry. Defined and explicit codes of ethics required in medical field, legal field, financial field, government, laboratory field, etc. Unsure why implementing this would be a problem, particularly in a regulatory compliance environment**

- Desire for payment responsibility in an investigation to be applied to regular compliance testing, as non-payment has adverse effect to labs
- Desire for more guidance on the standardization documents
- Concern about impact of QC requirement change ****most labs have little problem achieving the proposed limits, which reflect best practices and existing standardized testing methodologies from various lab industries. When they do have problems, it is usually due to poor quality control/quality assurance and inadequate instrument maintenance****
- Desire for labs to be permitted to retest without restriction before reporting results on the COA ****Inappropriate and excessive retesting practices has led to failing samples being retested until passing result is achieved and bypasses required regulatory retest process in NCCR 11.075. This has also led to enforcement actions regarding potency inflation and health advisories for failing products being retested until passing, misleading and potentially harming consumers****
- Concern about impact from increased glove change requirement during sampling ****preventing contamination during sampling is key for integrity of lab results****
- Concern that labs are owed outstanding debts by cultivators and producers and there is no requirement for these facilities to pay for services rendered
- Desire for mechanism to require payment by cultivators and producers to labs or to allow the labs to withhold test results until payment
- Desire for consistency in the retesting and appeals process to reduce lab-shopping
- Concerns about increased lab sample storage requirements. ****may possibly need increased storage capacity, depending on how many samples the lab receives****
- Desire for further discussion with CCB before implementation of regulatory changes
- Concern over the sampling requirement to collect from each container in a production run leading to increased testing costs ****this is a misunderstanding and was not the CCB's intent. The wording and intent can be clarified at the workshop****

Regulation 11 Indirect Adverse Impact

61% answered no or unsure/not affected, 39% responded yes.

Explanations included:

- Concern about fulfilling a COA retest labelling requirement without a mechanism to inform labs when a sample is a retest
- Desire for parity of detection limits for pesticides testing
- Concern that if labs cannot retest at will without limitation that there will be more testing failures ****inappropriate internal retesting practices lead to failing samples being reported as passing, potentially harms consumer, and must be restricted to known best lab practices. Inappropriate retesting practices have also led to enforcement actions regarding potency inflation and health advisories for failing products being retested until passing, potentially harming consumers. The concern should be reporting accurate, objective test results, not pleasing the client****
- Concern about impact to labs due to increased regulation and lack of payment from facilities
- Desire for industry as a whole to be held accountable for erroneous or misleading results
- Concerns about burdens or potential conflicts imposed by implementing testing method changes
- Desire for parity in glove use requirements among all facility types
- Desire for more guidance on new regulations

Regulation 11 Beneficial Impact

81 % responded no or unsure/not affected 19% responded yes

Explanations included:

- Beneficial impact to lab employee safety
- Beneficial impact by increasing parity and greater standardization between laboratories
- Cost benefits to non-laboratory facilities
- Reduction in testing failures and cost for facilities due to reduced required lab testing

Regulation 11 Indirect Beneficial Impact

87 % responded no or unsure/not affected, 13% responded yes

Explanations included:

- Indirect beneficial impact due to increased consumer confidence and safety due to increased standardization
- Indirect beneficial impact of less edible sample testing failures for homogeneity if weight is not factored into the homogeneity verification

3. **The manner in which the analysis was conducted, including the methods used to determine the impact of the proposed regulation on small businesses.**

The Agency used informed, reasonable judgment in determining that there would be minimal impact on small businesses due to the nature of the regulation changes. The proposed permanent regulations make minor changes to requirements already established and in place by license holders, and primarily seek to clarify and codify existing guidance.

The Agency analyzed the written responses from the Small Business Impact Survey and public comment from the September 26, 2023, workshop and January 31, 2024, solicitation of input meeting to determine the likely impact of the proposed permanent regulations on small businesses. This analysis included categorizing responses to identify themes and the frequency with which impacts were named. The Agency also looked at issues named with less frequency but could potentially have impact. The Agency has determined that there will be minimal impact to small businesses after making these revisions.

4. **The estimated economic effect of the proposed regulation on the small businesses which it is to regulate:**

Direct and indirect adverse effects

The Agency finds that there is minimal economic effect on small business.

The changes make updates to existing regulations by updating requirements upon small businesses in a manner that would not impose substantial burdens.

Direct and indirect beneficial effects

The Agency anticipates that those cannabis businesses that may be impacted will realize the beneficial economic impacts by providing clarity and standardization to the testing requirements made by the updated regulations. Additionally, restricting internal retesting to limited, established best practices may allow small business laboratories to gain savings in chemicals and supplies, and increase confidence in lab results. Ensuring highest-quality data and a level playing field reduces lab-shopping by cultivators and producers requires these facilities to be more compliant, increases consumer confidence in results, and ultimately may benefit the entire industry in increased sales. Further, any nominal costs to laboratories may be offset by both trust in the new testing requirements and regulations, as well as the current competitive climate, as active laboratory licenses have lowered from ten to seven in the past year.

5. **A description of the methods that the agency considered to reduce the impact of the proposed regulation on small businesses and a statement regarding whether the agency actually used any of those methods.**

The agency considered the feedback from the public and determined that revisions to the proposed language were not necessary to reduce the impact on small businesses but may be valuable to some extent for clarity and understanding.

6. **The estimated cost to the agency for enforcement of the proposed regulations.**

The proposed permanent regulations present no significant foreseeable or anticipated cost or decrease in costs for enforcement. The proposed changes merely make updates to regulations that are already in effect.

7. **If the proposed regulations provide a new fee or increases to existing fees, the total annual amount the agency expects to collect and the manner in which the money will be used.**

The proposed regulations do not increase or introduce new fees.

8. **If the proposed regulations include provisions which duplicate or are more stringent than federal, state or local standards regulating the same activity, an explanation of why such duplicative or more stringent provisions are necessary.**

The proposed permanent regulations do not overlap or duplicate any regulation of other federal, State or local governmental entities, but do reference regulatory authority granted by NRS 678A through NRS 678D.

9. **The reasons for the conclusion of the agency regarding the impact of these regulations on small businesses.**

The Agency has determined that there will be minimal adverse impacts to small cannabis businesses after revising the proposed permanent language based on comments received. Conversely, the Agency has determined that there will be beneficial impacts to small cannabis businesses based on the small changes required by the proposed updates to existing frameworks.

I hereby certify, to the best of my knowledge or belief, a concerted effort was made to determine the impact of the proposed regulations on small businesses and that this statement was properly prepared, and the information contained herein is accurate.

Dated this 12th day of April 2024.



James Humm
Executive Director
Nevada Cannabis Compliance Board

To receive a printed copy of this Small Business Impact Statement, contact:

Attn: Small Business Impact Summary – 4/30/24
Cannabis Compliance Board
700 E. Warm Springs Road #100
Las Vegas, Nevada 89119
Email: regulations@ccb.nv.gov